title: Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
abstract: Patients receiving large amounts of interferon (IFN), particularly cloned IFN-alpha, have been reported to develop antibodies to IFN-alpha. We used a neutralization technique bioassay to monitor 175 patients undergoing recombinant (r) IFN-alpha 2b therapy in an attempt to correlate antibody production to disease progression. Only 1 patient being treated for chronic myelogenic leukemia produced antibodies. Our findings indicate that rIFN-alpha 2b has minimal antigenicity, even when administered for prolonged periods of time.
authors.affiliation: Institute of Virology, University La Sapienza, Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Dianzani
authors.forename: G
authors.initials: G
authors.lastname: Antonelli
authors.forename: P
authors.initials: P
authors.lastname: Amicucci
authors.forename: A
authors.initials: A
authors.lastname: Cefaro
authors.forename: C
authors.initials: C
authors.lastname: Pintus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis* / Q000276:immunology; D000937:Antigen-Antibody Reactions; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000276:immunology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology* / Q000627:therapeutic use; D007558:Italy; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins
chemical_list: D000906:Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins